Background {#Sec1}
==========

Patients with systemic cancer are at substantial risk for development of cardiac masses (C~MASS~), including cardiac neoplasm (C~NEO~) and thrombus (C~THR~) \[[@CR1]--[@CR5]\]. Differentiation between C~NEO~ and C~THR~ impacts therapeutic decision-making, including use of anti-cancer therapies and anticoagulation. However, discrimination between the two based on anatomic appearance alone can be challenging, as C~NEO~ and C~THR~ can be similar in size and shape. Given the need to target therapeutic approaches and stratify prognosis in relation to C~MASS~ etiology, accurate differentiation between C~NEO~ and C~THR~ is of substantial importance.

One approach to discriminate between neoplasm and thrombus stems from tissue properties relating to presence or absence of vascular supply. C~NEO~ requires vascularity for tumorigenesis, whereas C~THR~ can be intrinsically defined based on avascularity. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging enables C~NEO~ to be differentiated from C~THR~ based on vascular composition. Prior research by our group and others has validated LGE-CMR as a highly accurate test for thrombus among non-cancer cohorts, including post-myocardial infarction and heart failure patients in whom LGE-CMR evidenced left ventricular (LV) thrombus has been shown to correlate with histopathology findings, and yield incremental utility (compared to anatomic imaging) for stratification of thrombo-embolic events \[[@CR6]--[@CR9]\]. More recently, we have employed LGE-CMR tissue characterization to identify C~NEO~ among patients with advanced systemic cancer, among whom prognosis paralleled cancer etiology and systemic disease burden \[[@CR3]\]. However, prior research to date has been limited to patient cohorts with *either* C~NEO~ *or* C~THR~, thereby prohibiting comparison of risk factors and differential prognosis associated with each of these two conditions.

This study employed LGE-CMR tissue characterization to assess C~NEO~ and C~THR~ among a broad cohort of at-risk patients with systemic cancer. Study aims were as follows: (1) identify cancer-associated risk factors predisposing to C~NEO~ and C~THR~; (2) compare anatomic location, function sequelae, and contrast-enhanced tissue properties of C~NEO~ and C~THR~; and (3) assess relative prognostic implications of C~NEO~ and C~THR~ compared to controls matched for cancer etiology and extra-cardiac disease burden.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The population included adults (≥18 years old) with systemic neoplasms with and without evidence of C~MASS~ as identified by late gadolinium enhancement (LGE-) CMR: C~MASS~ was defined as a discrete tissue prominence within either a cardiac chamber or pericardium, which demonstrated distinct enhancement pattern from surrounding myocardium. Patients with liquid tumors (i.e. leukemia) as well as primary cardiac malignancies were excluded. Established criteria \[[@CR3], [@CR7]--[@CR9]\] were used to distinguish C~MASS~ subtypes: (1) Neoplasm (C~NEO~) was defined as C~MASS~ with evidence of vascularity on LGE-CMR, defined by heterogeneous or diffuse contrast enhancement. (2) Thrombus (C~THR~) was defined as C~MASS~ without contrast enhancement. C~MASS~ + patients (i.e. C~NEO~ and C~THR~) were each matched (1:1) with patients with no cardiac mass (C~MASS~ -) on LGE-CMR but equivalent primary cancer etiology and disease stage.

Figure [1](#Fig1){ref-type="fig"} provides an overall schematic of the research protocol. In all patients, comprehensive clinical data were collected in a standardized manner, including cancer etiology, coronary heart disease risk factors, and anti-cancer therapies administered within 6 months of CMR. C~MASS~ data (imaging and clinical assessment) was collected as part of an ongoing registry of patients undergoing clinically indicated CMR, for which initial results (limited to C~NEO~ patients) have been partially reported \[[@CR3]\]. CMR was performed between September 2012 and January 2017 at Memorial Sloan Kettering Cancer Center (New York, New York, USA). Mortality status after CMR was assessed via review of electronic medical records so as to test prognosis in relation to presence and pattern of C~MASS~.Fig. 1Study Design. Schematic of overall study design, inclusive of baseline LGE-CMR (for mass tissue characterization) and subsequent clinical follow-up (for all cause mortality). Note that for all C~MASS~ + patients, etiology (C~NEO~ vs. C~THR~) was established based on presence or absence of enhancement on LGE-CMR

This study entailed analysis of imaging and ancillary data acquired for primarily clinical purposes; no dedicated interventions (imaging or otherwise) were performed for exclusively research purposes. Ethics approval for this protocol was provided by the Memorial Sloan Kettering Cancer Center Institutional Review Board, which approved a waiver of informed consent for analysis of pre-existing clinical data.

CMR protocol {#Sec4}
------------

CMR was performed on commercial (1.5 T \[89%\], 3.0 T \[11%\]) scanners (General Electric Healthcare, Waukesha, Wisconsin, USA). Exams included cine- and LGE-CMR, both of which were obtained in contiguous LV short-axis (from mitral annulus through the apex) and long-axis (2, 3, 4 chamber) imaging orientations. Cine-CMR utilized a balanced steady-state free precession (bSSFP) pulse sequence. LGE-CMR utilized an inversion recovery pulse sequence; images were acquired following gadolinium (0.2 mmol/kg) infusion. Conventional (inversion time \[TI\] \~300 msec) and "long TI" (TI 600 msec) were used to discern C~MASS~ vascularity concordant with prior methods applied and validated by our group \[[@CR3]\]: Conventional TI LGE-CMR was acquired uniformly in all patients; additional breath holds required for supplemental long TI LGE-CMR were tolerated in 97% (61/63) of C~MASS~ + patients (100% C~THR~, 95% C~NEO~).

Image analysis {#Sec5}
--------------

### C~MASS~ {#Sec6}

Whereas C~THR~ was intrinsically defined based on uniform absence of contrast uptake, C~NEO~ lesions were categorized based on two distinct enhancement patterns: Heterogeneous lesions manifested both discrete hyper- and hypoenhancement within a single mass; diffuse lesions manifested diffuse enhancement throughout the entire mass. Figure [2](#Fig2){ref-type="fig"} provides representative examples of C~MASS~ enhancement patterns on LGE-CMR.Fig. 2C~MASS~ Enhancement Patterns Identified by LGE-CMR. **a** C~NEO~: Representative examples of diffuse (left) and heterogeneous (right) enhancement as manifest on (long TI) LGE-CMR (lesions denoted within green circles). Corresponding cine-CMR images shown on bottom for purpose of anatomic localization. Both lesions (diffusely enhancing pericardial lesion adjacent to distal left ventricle (LV), heterogeneously enhancing right atrial (RA) lesion) identified in patients with advanced (stage IV) melanoma. **b** C~THR~: Typical non-enhancing lesion deemed consistent with avascular composition (thrombus). Note that RA localization of lesion, which was identified by LGE-CMR following placement of central catheter for therapeutic management of stage IV ovarian cancer

Quantitatively signal-to-noise (SNR) and contrast-to-noise (CNR) ratios on (long-TI) LGE-CMR were also used to assess enhancement patterns. Analyses were performed concordant with established methods previously applied by our group \[[@CR3]\]. For patients with multiple lesions, the largest mass (based on cumulative LGE-CMR review) was used for quantitative image analysis.

C~NEO~ and C~THR~ were scored in a binary manner (present or absent), and localized based on chamber location (right atrium \[RA\], right ventricle \[RV\], left atrium \[LA\], LV) or pericardial involvement. Anatomic and functional properties of lesions were measured on cine-CMR, including lesion size (area, perimeter, and orthogonal linear dimensions), border irregularity (perimeter/shortest orthogonal diameter), valvular adherence/regurgitation, and ventricular outflow tract obstruction.

### Cardiac chamber geometry {#Sec7}

Cine-CMR was used to measure cardiac structure and function, as well as to identify pericardial and pleural effusions. LV and RV chamber volumes and ejection fraction (EF) were quantified based on planimetry of end-diastolic and end-systolic short axis slices. LV mass (including papillary muscles and trabeculae) was measured at end-diastole. LA and RA areas were measured during atrial end-diastole in 4-chamber orientation.

Mode of spread and prognostic assessment {#Sec8}
----------------------------------------

Clinical documentation and extra-cardiac imaging (within 6 months of CMR) were reviewed to evaluate overall tumor burden. Extent of metastatic disease (outside of primary cancer organ) was evaluated in accordance with established methods based on number of major organ systems involved (central nervous system, head/neck, lung, pleura, liver, gastrointestinal, genitourinary, bones/soft tissue, thoracic and abdominal lymph nodes); a cumulative scoring system was used with each organ system assigned one point \[[@CR10]--[@CR12]\]. Electronic medical records were reviewed to assess all-cause mortality status. Time to event (death) was calculated in relation to CMR.

Statistical methods {#Sec9}
-------------------

Comparisons between groups with or without C~MASS~, as well as between C~MASS~ subtypes (C~NEO~ vs C~THR~) were made using Student's t-test (expressed as mean ± standard deviation) for continuous variables, and Chi-square or Fishers exact tests for categorical variables: Paired testing (e.g. paired t-test or McNemar's test) were employed for matched case-control comparisons. The Kaplan-Meier method estimated the survival function. Cox proportional hazards model with a shared gamma frailty were used to compare mortality risk between groups adjusting for the matching. Receiver operating characteristics (ROC) analysis was used to evaluate overall diagnostic test performance of given imaging parameters (e.g. lesion size, SNR, CNR) for differentiation between LGE-CMR designated C~NEO~ and C~THR~, and to derive cutoffs for maximal sensitivity and specificity. Statistical calculations were performed using SPSS 24.0 (SPSS Inc. \[International Business Machines, Inc., Armonk, New York, USA\]) and Stata 13.0 for Windows. Two-sided *p* \< 0.05 was considered indicative of statistical significance.

Results {#Sec10}
=======

Population characteristics {#Sec11}
--------------------------

The study population comprised 126 patients with systemic neoplasms undergoing CMR, including 63 with cardiac masses (C~MASS~). Table [1](#Tab1){ref-type="table"} reports clinical and imaging characteristics of the population, including comparisons between C~MASS~ affected patients and matched controls, as well as between affected patients within each C~MASS~ subtype (C~NEO~, C~THR~). As shown, C~MASS~ + patients had a slightly higher burden of extra-cardiac disease as assessed based on number of cancer-affected organ systems (*p* = 0.02), but were similar with respect to age, gender, as well as cardiac remodeling and functional indices (all *p* = NS). Cancer subtype was verified by pathology in all patients; 13% (*n* = 5) of patients with C~NEO~ underwent tissue-based verification of mass etiology: Results demonstrated uniform concordance between biopsy and CMR-designation of C~NEO~ based on mass-associated contrast-enhancement.Table 1Population CharacteristicsOverall\
(*n* = 126)C~MASS~ +\
(n = 63)C~MASS~ -\
(n = 63)pC~MASS~ +pC~NEO~\
(*n* = 40)C~THR~\
(*n* = 23)Clinical Characteristics Age (years)57 ± 1557 ± 1556 ± 160.5860 ± 1453 ± 160.10 Male gender56% (70)54% (34)57% (36)0.8555% (22)52% (12)0.83 Body Surface Area (m^2^)1.8 ± 0.31.8 ± 0.31.9 ± 0.30.491.8 ± 0.31.8 ± 0.20.66Leading Cancer Etiologies^a^ Gastrointestinal19% (24)19% (12)19% (12)1.0015% (6)26% (6)0.33 Sarcoma16% (20)16% (10)16% (10)1.0020% (8)9% (2)0.30 Lymphoma14% (18)14% (9)14% (9)1.005% (2)30% (7)0.009 Lung14% (18)14% (9)14% (9)1.0018% (7)9% (2)0.47 Genitourinary13% (16)13% (8)13% (8)1.0013% (5)13% (3)1.00Cancer Stage  I - III5% (6)5% (3)5% (3)1.000%13% (3)0.045  IV95% (120)95% (60)95% (60)1.00100% (40)87% (20)0.045Disease Extent (\# organs involved)2.7 ± 2.03.1 ± 2.12.4 ± 1.80.023.6 ± 2.02.3 ± 2.10.02Anti-Cancer Regimen Chemotherapy  Alkylating agent32% (40)29% (18)36% (22)0.4831% (12)26% (6)0.70  Platinum36% (45)41% (26)30% (19)0.2550% (20)26% (6)0.06  Antimetabolite37% (47)40% (25)35% (22)0.7138% (15)44% (10)0.64  Anthracycline25% (32)25% (16)25% (16)1.0025% (10)26% (6)0.92  Mitotic inhibitor37% (47)37% (23)38% (24)1.0035% (14)39% (9)0.74  Biologic agents32% (40)32% (20)32% (20)1.0030% (12)35% (8)0.70  Radiation Therapy36% (45)37% (23)35% (22)1.0035% (14)39% (9)0.74Antiplatelet Therapy^b^24% (30)19% (12)29% (18)0.3115% (6)26% (6)0.33Anticoagulation Therapy^c^26% (33)35% (22)18% (11)0.0430% (12)16% (10)0.28Coronary Artery Disease11% (14)8% (5)14% (9)0.425% (2)13% (3)0.35 Atherosclerosis Risk Factors  Hypertension35% (44)32% (20)38% (24)0.5635% (14)26% (6)0.46  Diabetes mellitus10% (12)5% (3)14% (9)0.158% (3)0% (0)0.29  Hypercholesterolemia26% (33)21% (13)32% (20)0.2515% (6)30% (7)0.20  Tobacco use46% (58)46% (29)46% (29)1.0038% (15)61% (14)0.07Cardiac Morphology and Function Left Ventricle  Ejection fraction (%)61 ± 1263 ± 959 ± 150.0963 ± 962 ± 100.51  Ejection fraction \<50%15% (19)12% (7)20% (12)0.2711% (4)13% (3)1.00  Stroke volume (mL)70 ± 2470 ± 2570 ± 220.9867 ± 2374 ± 290.31  End-diastolic volume (mL)119 ± 45113 ± 43125 ± 470.18107 ± 38122 ± 500.19  End-systolic volume (mL)49 ± 3443 ± 2355 ± 420.0640 ± 2048 ± 280.19  End-diastolic diameter (cm)4.7 ± 0.74.6 ± 0.74.8 ± 0.80.084.5 ± 0.64.8 ± 0.70.06  Myocardial mass (gm)118 ± 55121 ± 69115 ± 370.53126 ± 79112 ± 510.44 Right Ventricle  Ejection fraction (%)53 ± 853 ± 953 ± 80.9253 ± 954 ± 80.47  Ejection fraction \<50%17% (22)22% (13)15% (9)0.4527% (10)13% (3)0.33  Stroke volume (ml)69 ± 2669 ± 2671 ± 250.6966 ± 2374 ± 310.27  End-diastolic volume (mL)134 ± 50129 ± 47139 ± 520.23127 ± 43135 ± 550.49  End-systolic volume (mL)64 ± 3361 ± 2667 ± 380.2461 ± 2662 ± 270.88 Atria  Left atrial area (cm^2^)20 ± 720 ± 720 ± 60.9719 ± 721 ± 80.40  Right atrial area (cm^2^)19 ± 719 ± 619 ± 70.9419 ± 619 ± 60.71^a^Other cancer etiologies for C~NEO~: melanoma/skin (13% \[n = 5\]), endocrine (10% \[n = 4\]), head/neck (5% \[n = 2\]), and breast (3% \[*n* = 1\])^b^Aspirin or thienopyridine^c^Warfarin, non-vitaming K oral anticoagulant, or full dose low molecular weight heparin

Regarding comparisons between C~MASS~ subtypes, Table [1](#Tab1){ref-type="table"} demonstrates that C~NEO~ and C~THR~ differed with respect to cancer etiology: Among patients with C~THR~, lymphoma (30%) and gastrointestinal tumors (26%) were the most common underlying malignancies. Among patients with C~NEO~, sarcoma (20%) and lung (18%) were most common, although cancers not typically associated with cardiac involvement (e.g. endocrine, head and neck carcinomas) were also included in the study cohort. Whereas the majority of patients with C~NEO~ (100%) and C~THR~ (87%) had pre-existing stage IV cancer (irrespective of cardiac involvement), systemic disease burden --based on total number of non-cardiac organ systems involved - was higher among patients with C~NEO~ vs. those with C~THR~ (*p* = 0.02).

Anatomic distribution and Sequelae {#Sec12}
----------------------------------

Table [2](#Tab2){ref-type="table"} compares anatomic distribution and sequelae of C~NEO~ and C~THR~. As shown, right-sided chamber involvement (i.e. RA or RV) occurred in the majority of patients with either condition, prevalence of which was similar between C~NEO~ and C~THR~ (*p* = 0.14). C~THR~ more commonly localized to the RA (78%; *p* \< 0.001 vs. C~NEO~) -- nearly all cases (17/18) of right atrial C~THR~ were associated with central venous catheters inserted for chemotherapy administration. Whereas nearly half (43%) of patients with C~NEO~ had RV involvement (*p* = 0.001 vs. C~THR~), individual chamber location was highly variable. Regarding distribution, rates of multi-chamber involvement tended to be higher among C~NEO~ affected patients (23% vs. 4%, *p* = 0.08).Table 2Anatomic Features and SequeleaC~NEO~C~THR~pAnatomic Distribution Chamber Involvement  Right atrium25% (10)78% (18)\<0.001  Right ventricle43% (17)4% (1)0.001  Left atrium15% (6)4% (1)0.41  Left ventricle28% (11)17% (4)0.36  Right atrium or right ventricle60% (24)78% (18)0.14  Multichamber involvement^a^23% (9)4% (1)0.08 Pericardial involvement30% (12)0% (0)0.002 Valvular adherence  Outflow tract or valvular stenosis13% (5)0% (0)0.15  Valvular regurgitation20% (8)17% (4)1.00 Effusion  Pericardial25% (10)17% (4)0.48  Pleural53% (21)17% (4)0.006^a^Among C~NEO~ patients with multichamber involvement (23% \[*n* = 9\]), anatomic distribution was as follows: Left and right ventricle (8% \[n = 3\]); right atrium and right ventricle (8% \[*n* = 3\]); left atrium and left ventricle (3% \[n = 1\]); left and right atria (3% \[*n* = 1\]); left atrium, left ventricle and right ventricle (3% \[n = 1\])

Despite increased cardiac disease burden, assessed based on extent of chamber involvement and primary lesion size, C~NEO~ was rarely associated with functional impairment or localized effusions on CMR. For example, only 13% of C~NEO~ cases were associated with outflow tract or valvular stenosis, and only 25% were associated with pericardial effusions (8/10 in context of pericardial metastases).

Tissue characterization {#Sec13}
-----------------------

Figure [3a](#Fig3){ref-type="fig"} compares SNR and CNR between visually scored C~NEO~ and C~THR~. As shown, both quantitative indices were higher within C~NEO~ vs. C~THR~ (SNR 29.7 ± 20.4 vs. 15.0 ± 11.4 \| CNR 13.1 ± 13.0 vs. 1.6 ± 1.0; both *p* \< 0.01), consistent with increased contrast uptake due vascular supply. Regarding C~NEO~ subtypes, data shown in Fig. [3b](#Fig3){ref-type="fig"} indicate that lesions with diffuse enhancement tended to have higher SNR than did those with heterogeneous enhancement, although this was not statistically significant (38.3±27.5 vs. 24.0±11.7; *p* = 0.08): Neoplasm with either enhancement pattern had higher SNR than did C~THR~ (15.0 ± 11.4; both *p* \< 0.05). CNR was higher among lesions with visually scored heterogeneous enhancement (18.3±14.3) compared to either diffusely enhancing C~NEO~ (5.2±3.9; *p* \< 0.001) or C~THR~ (1.6±1.0; p \< 0.001), consistent with interspersed regions of tissue vascularity (enhancement) and tissue necrosis (non-enhancement).Fig. 3Quantitative Tissue Properties of Cardiac Neoplasm and Thrombus. **a** SNR (left) and CNR (right) compared between C~NEO~ and C~THR~ (data shown as overall distribution \[line bars\] together with 25--75% distribution \[box\], and median \[central line\]). Note that SNR and CNR were generally higher for C~NEO~, consistent with contrast-enhancement secondary to vascular supply. **b** SNR and CNR comparisons inclusive of C~NEO~ subtypes (diffuse and heterogeneous enhancement). Increased CNR within heterogeneously enhancing lesions (*p* \< 0.001 vs. other types) consistent with interspersed regions with and without adequate vascular supply

Tissue characterization differences between cardiac masses were paralleled by differences in anatomic features. As shown in Table [3](#Tab3){ref-type="table"}, overall comparisons between C~NEO~ and C~THR~ demonstrated the former to typically be larger, whether assessed based on area or linear dimensions (both p \< 0.05). However, further stratification demonstrated differences to vary based on C~NEO~ pattern of enhancement: Neoplastic lesions with heterogeneous enhancement tended to be larger than those with diffuse enhancement, whether quantified by area (*p* \< 0.001) or linear dimensions (*p* \< 0.1). Of note, while all anatomic indices were larger for heterogeneously enhancing lesions compared to C~THR~, (*p* \< 0.005), diffusely enhancing C~NEO~ lesions and C~THR~ were not significantly different in size (*p* \> 0.05). Figure [4](#Fig4){ref-type="fig"} illustrates ROC curves concerning overall performance of CNR, SNR, and lesion size (area, maximal length) for differentiation between C~MASS~ subtypes (C~NEO~, C~THR~). Table [4](#Tab4){ref-type="table"} reports diagnostic test variables calculated using cutoffs derived from corresponding ROC curves. As shown, AUC (0.88 \[0.79--0.97\]) and diagnostic accuracy (85%) were highest for CNR, consistent with use of contrast-enhancement as the criterion for C~NEO~.Table 3Tissue Characteristics in Relation to Anatomic PropertiesC~NEO~C~THR~*p*C~NEO~*p* (HETERO VS DIFFUSE)*p* (HETERO VS. THR)*p* (DIFFUSE VS. THR)C~NEO-HETERO~\
(*n* = 25)C~NEO-DIFFUSE~\
(*n* = 15)Area (cm^2^)17.3 ± 23.82.0 ± 1.5\<0.00125.8 ± 26.63.0 ± 2.7\<0.001\<0.0010.21Perimeter (cm)16.0 ± 13.35.9 ± 2.7\<0.00121.6 ± 13.96.6 ± 2.6\<0.001\<0.0010.45Maximal Length (cm)5.8 ± 4.92.3 ± 1.6\<0.0017.0 ± 3.83.9 ± 5.90.06\<0.0010.22Orthogonal Length (cm)3.3 ± 2.52.0 ± 2.00.044.1 ± 2.52.0 ± 2.10.010.0030.96Perimeter/Min Length5.3 ± 2.14.6 ± 2.80.265.7 ± 2.34.7 ± 1.40.130.150.94 Fig. 4Receiver Operating Characteristics Curves. ROC curves for CNR, SNR, and lesion size (length, area) as indices for discriminating between C~MASS~ types. As shown, CNR yielded highest overall diagnostic performance (based on area under the curve \[AUC\]) for differentiating between C~NEO~ and C~THR~. AUC associated *p*-values reflect comparisons to null hypothesis (area = 0.5) Table 4Diagnostic Test Performance in Relation to Quantitative Signal Intensity and Lesion Size^a^SensitivitySpecificityAccuracyPositive Predictive ValueNegative Predictive ValueSignal Intensity Variables Contrast-to-noise ratio76% (29/38)100% (23/23)85% (52/61)100% (29/29)72% (23/32) Signal-to-noise ratio71% (27/38)83% (19/23)75% (46/61)87% (27/31)63% (19/30)Lesion Size Variables Area (cm^2^)73% (29/40)83% (19/23)76% (48/63)88% (29/33)63% (19/30) Maximal length (cm)63% (25/40)91% (21/23)73% (46/63)93% (25/27)58% (21/36)^a^Cutoffs derived (for maximum sensitivity and specificity) from ROC curves shown in Fig. [4](#Fig4){ref-type="fig"} (parameter-based cutoffs as follows: CNR 4.50, SNR 19.36, area 2.76, maximum length 3.27)

Clinical outcomes {#Sec14}
-----------------

Among patients with C~NEO~, 8% (*n* = 3) underwent resection, 43% (*n* = 17) had a change in chemotherapy regimen and 13% (*n* = 5) underwent targeted radiation of the heart and/or mediastinum within 6 months after CMR. Less than half of C~NEO~ patients were treated with anticoagulation, as compared to nearly all patients with C~THR~ (38% vs. 96%, *p* \< 0.001). Regarding embolic events, pulmonary embolism was more common among patients with C~MASS~ (18% vs. 6%, *p* = 0.12), as well as among patients with right sided C~MASS~ + compared to controls (C~MASS~ -) or C~MASS~ + patients with isolated left sided involvement (24% vs. 6%, *p* = 0.004): Among C~MASS~ sub-types, pulmonary embolism rates were similarly high among patients with C~NEO~ (20%) and C~THR~ (13%). Rates of cerebrovascular accident were identical between patients with and without C~MASS~ (6% vs. 5%, *p* = 1.00), and did not differ when patients were further stratified by left sided C~MASS~ location (10% vs. 5%, *p* = 0.31).

Patient mortality was assessed following CMR to test the impact of C~MASS~ related tissue properties on clinical prognosis. Median duration of post-CMR follow-up was 2.5 years (IQR 1.1--3.8) among survivors; median survival after imaging was 1 year. Figure [5](#Fig5){ref-type="fig"} provides Kaplan Meier survival curves of C~NEO~ and C~THR~ affected patients, as well as controls (C~MASS~) matched for primary cancer type and stage. As shown, mortality risk was similar between C~THR~ affected patients and controls (hazard ratio \[HR\] = 0.82 \[CI 0.35--1.89\], *p* = 0.64). In contrast, C~NEO~ affected patients tended towards slightly higher mortality compared to controls, although differences were non-significant (HR = 1.50 \[CI 0.90--2.49\], *p* = 0.12). Risk for death by 6 months post-CMR among C~NEO~ and C~THR~ patients compared to cancer-matched controls without cardiac involvement were (C~NEO~: 50% vs. 38% \| C~THR~: 22% vs. 22%); corresponding risks at 1 year were proportionately higher (C~NEO~: 61% vs. 57% \| C~THR~: 35% vs. 35%).Fig. 5Mortality Status. Kaplan Meier survival curves for patient groups partitioned based on C~MASS~ status (solid blue = C~NEO~, dotted blue = C~NEO~ control; solid red = C~THR~, dotted line = C~THR~ control): For both C~NEO~ and C~THR~, controls were matched for primary cancer type and stage. Note higher mortality among patients with C~NEO~ vs. C~THR~ (*p* = 0.002); C~THR~ conferred similar mortality risk compared to respective cancer-matched controls whereas mortality associated with C~NEO~ was slightly higher albeit non-significant

Comparisons between C~NEO~ and C~THR~ affected patients demonstrated prognosis to be markedly worse among the former (HR = 3.13 \[CI 1.54--6.39\], *p* = 0.002); mortality was approximately 2-fold higher among patients with C~NEO~ at 6 months (50% vs. 22%) and at 1-year (61% vs. 35%) post-CMR. Of note, C~NEO~ was associated with increased mortality risk, whereas lesion size -- as assessed via area (HR = 0.99 per cm^2^ \[CI 0.98--1.01\], *p* = 0.40) or maximal diameter (HR = 0.98 per cm \[CI 0.91--1.06\], *p* = 0.61) was not. Outcomes were not significantly different between C~NEO~ patients with heterogeneous and diffusely enhancing lesions (HR = 1.14 \[CI: 0.60--2.26\], *p* = 0.70). Similarly, among the small number of patients with multichamber involvement mortality did not statistically differ compared to C~MASS~ + patients with lesions confined to a single cardiac chamber (HR = 1.40 \[CI 0.62--3.16\], *p* = 0.41).

Discussion {#Sec15}
==========

This is the largest study to date examining anatomic pattern, tissue properties, and differential prognostic implications of CMR-evidenced cardiac masses (C~MASS~ +) among patients with systemic cancer. Key findings are as follows. First, among a broad cancer cohort for which C~MASS~ + etiology was defined based on presence or absence of contrast enhancement on LGE-CMR, likelihood of C~NEO~ paralleled extra-cardiac disease burden -- as evidenced by higher total number of non-cardiac organ systems involved among patients with C~NEO~ vs. C~THR~ (*p* = 0.02). Second, whereas C~THR~ was classified based on uniform absence of enhancement, two distinct C~NEO~ patterns were identified - heterogeneous and diffuse enhancement. CNR was highest among lesions with heterogeneous enhancement (*p* \< 0.001) - consistent with interspersed regions of tissue vascularity and tissue necrosis. C~NEO~ lesions with heterogeneous enhancement were larger than C~NEO~ lesions with diffuse enhancement, as well as C~THR~ (both *p* \< 0.05). Conversely, diffusely enhancing C~NEO~ lesions and C~THR~ were of similar size (*p* = NS). Finally, follow-up data demonstrated C~THR~ to confer similar mortality risk compared to cancer-matched controls without cardiac involvement (HR = 0.82 \[CI 0.35--1.89\], *p* = 0.64) whereas mortality among C~NEO~ affected patients was slightly higher but not significantly different vs. matched controls (HR = 1.50 \[CI 0.90--2.49\], *p* = 0.12). Follow-up data also showed mortality to be increased among patients with LGE-CMR defined C~NEO~ compared to those with C~THR~ (HR = 3.13 \[CI 1.54--6.39\], *p* = 0.002); outcomes were similar when patients were stratified based on lesion size (HR = 0.99 per cm^2^ \[CI 0.98--1.01\], *p* = 0.40).

Regarding the diagnostic approach employed in our study, it is important to recognize the concept that C~NEO~ can be distinguished from C~THR~ based on contrast-enhancement is not modality specific: For example, Kirkpatrick et al. - studying a cohort in whom pathology and anticoagulation response were respectively used to verify C~NEO~ and C~THR~, reported that contrast uptake on perfusion echocardiography was uniformly associated with malignant C~NEO~ whereas hypo-enhancement was associated with C~THR~ \[[@CR13]\]. Given the established concept that C~NEO~ manifests contrast-enhancement due to intrinsic vascular supply, and that vascularity is a key component for cellular proliferation/lesion growth, our finding that C~NEO~ were generally larger than C~THR~ is consistent with general concepts in tumor biology, for which lesion growth has been shown to correlate with vascular supply \[[@CR14]--[@CR16]\]. Our results also show that cancer-associated enhancement on LGE-CMR can vary in pattern, manifesting as diffuse or heterogeneous enhancement. The notion that heterogeneous enhancement on CMR is a marker of tissue necrosis has also been demonstrated via non-cardiac magnetic resonance imaging (MRI): Among patients with hepatic cell carcinoma, central hypo-enhancement on liver MRI has been shown to correspond to pathology-evidenced coagulation necrosis \[[@CR17]\]. Regarding mechanism, in-vitro and ex-vivo studies have shown tumor necrosis to stem from mismatch between tumor growth and vascular supply, leading to cell death and tissue necrosis \[[@CR18], [@CR19]\]. It is possible that heterogeneous enhancing C~NEO~ may be partially attributable to surface thrombosis, as can be superimposed on necrotic and/or hypercoagulable tissue. Whereas our study did not directly perform serial imaging to directly assess tumor growth or therapeutic response, our finding of increased lesion size among patients with heterogeneous compared to diffusely enhancing C~NEO~ is consistent with the notion that heterogeneous enhancement stems from underlying differences in tumor growth.

Our current findings add to growing literature demonstrating C~MASS~ + tissue characterization to provide diagnostic and prognostic utility among cancer and non-cancer cohorts. Prior data from our group has shown an association between LV thrombus (defined by LGE-CMR) and risk for embolic events among heart failure cohorts \[[@CR6], [@CR7]\]. Similarly, multicenter clinical trial data has shown LGE-CMR evidenced LV thrombus to predict all cause mortality \[[@CR20]\]. Among patients with advanced cancer, recent data from our group has shown C~NEO~ to be associated with poor prognosis (44% 6-month mortality) \[[@CR3]\]. However, this analysis was limited to patients with LGE-CMR defined C~NEO~, thereby precluding study of differential prognosis associated with presence or absence of lesion-associated contrast-enhancement. Our current study addresses this key knowledge gap -- findings support incremental utility of tissue characterization via LGE-CMR (vs. anatomic assessment via techniques such as cine-CMR or echo) to guide therapeutic decision-making and prognostic risk stratification for cancer-patients with cardiac masses.

It is noteworthy that while mortality rates markedly differed between patients with C~NEO~ and C~THR~, prognosis of each group was similar to that of cancer-affected controls (C~MASS~ -) matched for disease etiology and extent of extra-cardiac disease. Regarding C~THR~, we speculate that this is attributable to the fact that this condition is treatable (via anticoagulation) and that the majority of thrombosis was limited to the right atrium and thus not exposed to high pressure, systemic circulatory conditions predisposing to life-threatening embolization. Consistent with this notion, our findings suggest that patients with C~THR~ on LGE-CMR were near uniformly treated with anticoagulants (96%). Regarding C~NEO~, our finding of a numerically higher although non-significant mortality rates vs. controls (*p* = 0.12) suggests that the primary determinant of outcome relates to cancer etiology and burden of systemic disease, for which cardiac involvement is only one component similar to that of other organ systems.

Several limitations should be noted. First, our study population was derived from patients with C~MASS~ referred for clinical CMR at a single tertiary care cancer center: C~MASS~ affected cases and controls were specifically matched for cancer etiology and extent of extra-cardiac disease to test the additive impact of presence and type of C~MASS~ on survival. In this context, it is important to recognize that mortality rates among controls may not reflect those of a general population of advanced cancer patients, but rather survival in a select group for which cancer etiology and stage were similar to that of affected (C~MASS~ +) cases. Mortality estimates should also be interpreted keeping in mind that our study included patients at various times after their diagnoses and only evaluated patients who were healthy enough to undergo CMR. Second, this study used LGE-CMR to define C~MASS~ type (i.e. neoplasm or thrombus) based on presence or absence of contrast uptake so as to test an established imaging approach well validated based on prior research by our group and others \[[@CR3], [@CR6]--[@CR9], [@CR20]\]. Alternative imaging strategies such as perfusion and T1 mapping can also measure contrast-enhancement in a manner similar to LGE-CMR -- these methods were not tested in our study, but hold potential for quantitative assessment of C~MASS~ associated enhancement. Third, our estimates of diagnostic test performance (e.g. accuracy) for given imaging parameters (e.g. CNR, SNR) were assessed using cutoff values chosen from the same data and are likely optimistic. Finally, it should be noted that our study included a broad array of patients with different primary cancer diagnoses. Whereas C~MASS~ + patients were matched (1:1) to C~MASS~ - patients with equivalent cancer type and stage so as to test impact of presence and type of C~MASS~ on prognosis, heterogeneity in cancer etiology is a potential confounding variable that could have impacted our results. Further larger studies in uniform cancer populations are needed to examine impact of C~MASS~ tissue properties on cancer-associated outcomes.

Conclusions {#Sec16}
===========

Findings of this study demonstrate that among cancer patients with C~MASS~, presence or absence of LGE-CMR evidenced contrast-enhancement is a powerful prognostic indicator: C~NEO~ as defined by LGE-CMR tissue characterization conferred markedly poorer prognosis than C~THR~, whereas anatomic assessment of lesion size via cine-CMR did not stratify mortality risk. Both C~NEO~ and C~THR~ are associated with similar prognosis compared to C~MASS~ - controls matched for cancer type and disease extent. Future, multicenter research among patients with C~NEO~ is warranted to test whether prognosis or therapeutic response varies based on pattern or extent of enhancement as measured by LGE-CMR or emerging CMR tissue characterization approaches.
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